Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact firstname.lastname@example.org
SOURCE Metacrine, Inc.
SAN DIEGO, March 7, 2018 /PRNewswire/ -- Metacrine, Inc., an innovative biotechnology company focused on drug development, today announced that Ken Song, MD, President and CEO, will participate in two upcoming investor conferences.
Dr. Song will give a corporate presentation and participate in a NASH panel discussion at the 30th Annual ROTH Conference taking place at the Ritz-Carlton in Dana Point, CA. The corporate presentation will take place Monday, March 12, 2018 at 3:30 p.m. Pacific in Green Salon-3. The panel presentation "Not All Fruits are the Same, But What About FXR Agonists?" will take place earlier that same day at 10 a.m. Pacific in Green Salon-3. The presentation is part of a two-day panel program on the latest topics and developments in NASH/PBC drug development.
Dr. Song will also give a corporate presentation at the H.C. Wainwright & Co. Second Annual NASH Investor Conference taking place at the St. Regis Hotel in New York. The presentation will take place Monday, March 19, 2018 at 4:40 p.m. Eastern.
Metacrine is a privately held biotechnology company headquartered in San Diego, CA. The company is focused on efficiently developing innovative drugs that materially benefit patients with metabolic disease. For more information, visit www.metacrine.com.
View original content with multimedia:http://www.prnewswire.com/news-releases/metacrine-to-present-at-30th-annual-roth-conference-and-hc-wainwright--co-2nd-annual-nash-investor-conference-300609617.html
©2017 PR Newswire. All Rights Reserved.